Testing a new card to ensure chemotherapy drug quality in Africa
Adapting a point of use test card, the chemoPAD, for protecting chemotherapy drug quality in sub-Saharan Africa
This study is testing a new tool called the chemoPAD that helps check if chemotherapy drugs are safe and effective, so patients in countries like Ethiopia, Malawi, Cameroon, and Kenya can get the best treatment for cancer.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project ID | NIH-10909177 on NIH RePORTER |
What this research studies
This research aims to validate a new technology called the chemoPAD, which is a point-of-use test card designed to detect poor quality chemotherapy drugs in sub-Saharan Africa. The project will adapt the chemoPAD to screen various injectable chemotherapy medications and utilize a mobile app to analyze the results. By collaborating with local partners in countries like Ethiopia, Malawi, Cameroon, and Kenya, the research will assess the quality of chemotherapy products and help improve cancer treatment in these regions. The goal is to ensure that patients receive effective and safe chemotherapy by identifying falsified or substandard drugs.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients receiving chemotherapy in sub-Saharan African countries.
Not a fit: Patients receiving chemotherapy outside of sub-Saharan Africa or those not using injectable chemotherapy drugs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the safety and effectiveness of chemotherapy treatments for cancer patients in low- and middle-income countries.
How similar studies have performed: Other research has shown promise in using point-of-use testing technologies for drug quality assessment, indicating potential success for this approach.
Where this research is happening
Notre Dame, United States
- University of Notre Dame — Notre Dame, United States (Active)
Researchers
- Principal investigator: Lieberman, Marya — University of Notre Dame
- Study coordinator: Lieberman, Marya
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.